jueves, 23 de mayo de 2019

Medical News | Medical Articles: Solutions for Evaluation of CAR Expressions

Medical News | Medical Articles

 
 May 22, 2019 
 Immunology 
 The latest immunology news from News Medical 
 #ALT#Solutions for Evaluation of CAR Expressions

Chimeric antigen receptor T-cell therapy is a new cancer treatment. T-cells are taken from the patient and genetically engineered to express a chimeric receptor that recognizes a specific tumor-associated antigen. The resulting CAR-expressing T cells, when reintroduced into the patient, target and eliminate TAA-expressing tumor cells. Evaluating CAR expression is an essential step in the production of CAR-T cells. ACROBiosystems has developed an extensive collection of recombinant proteins to support CAR-T therapy development, including fluorescent-labeled target antigens and pre-biotinylated proteins, uniquely suitable for CAR expression evaluation.

Read Full Article Here
 
 
  KeysightA Guide to Identifying Histone Modifications
 
Cheat sheet: identify which histone modification marks which genomic element. Abcam have produced this guide for users so that they don’t have to continuously reference the literature to find these answers.

Learn more about how we provide workflow assistance and the requirements that should be met before studying the sample. 

 
Find Out More
 
 
   New research uncovers how superbug evades the immune system to cause infectionNew research uncovers how superbug evades the immune system to cause infection
 
New research led by the University of Sheffield has discovered how a hospital superbug evades the immune system to cause infection - paving the way for new treatments.
 
 How to Reduce Background Noise in IHC
 
How to Reduce Background Noise in IHCImmunohistochemistry (IHC) is a popular method for visualizing the presence, concentration, and distribution of molecules within tissue. The method utilizes specific antibodies that bind to target antigens and is a very effective way of studying tissue architecture. However, cross-reactivity, low specificity and problems with antibody preparation can cause serious issues with background noise.
 
 
 Host-cell enzymes vital for inhibiting mutant forms of coronavirus, study finds
 
Host-cell enzymes vital for inhibiting mutant forms of coronavirus, study findsHost-cell enzymes called PARP12 and PARP14 are important for inhibiting mutant forms of a coronavirus, according to a study published May 16 in the open-access journal PLOS Pathogens by Stanley Perlman of the University of Iowa, Anthony Fehr of the University of Kansas, and colleagues.
 
 
 cGAS–STING Pathway Steps, Regulation, and Oncogenesis
 
cGAS–STING Pathway Steps, Regulation, and OncogenesisThe cGAS–STING pathway is part of the innate immune system and is involved in the detection of cytosolic deoxyribonucleic acid (DNA). Post-detection, this pathway triggers the defense mechanisms that can lead to cell senescence.
 
 
 Immune system discovery could inform the development of new stem cell therapies
 
Immune system discovery could inform the development of new stem cell therapiesA discovery of how stem cells are protected from viruses could inform the development of therapies for use in medicine, research suggests. The finding could help research aimed at boosting the immune response of stem cells - early stage cells with the potential to become specialized tissues - for use in treating disease or damaged tissues.
 
 
 Circadian rhythm influences immune responses across a range of diseases
 
Circadian rhythm influences immune responses across a range of diseasesResearchers in Switzerland have conducted a review of studies looking at how circadian rhythm affects the immune response and severity of illnesses ranging from heart attack to allergy.
 
 
 New gene therapy cures babies with fatal 'Bubble Boy' disease
 
New gene therapy cures babies with fatal 'Bubble Boy' diseaseA new gene therapy created by US researchers appears to have cured eight infant boys born with a rare genetic disorder referred to as “Bubble Boy” disease. The new therapy was shown to safely correct the immune systems of eight infants affected by X-linked severe combined immunodeficiency (X-SCID).
 

No hay comentarios:

Publicar un comentario